The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity

Girlandia Alexandre Brasil, Mirian de Almeida Silva-Cutini, Flávia de Souza Andrade Moraes, Thiago de Melo Costa Pereira, Elisardo Corral Vasquez, Dominik Lenz, Nazaré Souza Bissoli, Denise Coutinho Endringer, Ewelyne Miranda de Lima, Vinicia Campana Biancardi, June Ferreira Maia, Tadeu Uggere de Andrade

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: We aimed to evaluate whether long-term treatment with the soluble non-bacterial fraction of kefir affects mean arterial pressure (MAP) and cardiac hypertrophy through the modulation of baroreflex sensitivity, ACE activity, and the inflammatory-to-anti-inflammatory cytokine ratio in spontaneously hypertensive rats (SHRs). Methods: SHRs were treated with the soluble non-bacterial kefir fraction (SHR-kefir) or with kefir vehicle (SHR-soluble fraction of milk). Normotensive control Wistar Kyoto animals received the soluble fraction of milk. All treatments were administered by gavage (0.3 mL/100g/body weight), once daily for eight weeks. At the end, after basal MAP and Heart Rate (HT) measurement, barorreflex sensitivity was evaluated through in bolus administrations of sodium nitroprusside and phenylephrine (AP50 [arterial pressure 50%], the lower plateau, and HR range were measured). ACE activity and cytokines (TNF-α and IL-10) were evaluated by ELISA. Cardiac hypertrophy was analysed morphometrically. Results: Compared to SHR control, SHR-kefir exhibited a significant decrease in both MAP (SHR: 184 ± 5; SHR-Kefir: 142 ± 8 mmHg), and HR (SHR: 360 ± 10; SHR-kefir: 310 ± 14 bpm). The non-bacterial fraction of kefir also reduced cardiac hypertrophy, TNF-α-to-IL10 ratio, and ACE activity in SHRs. SHR-kefir baroreflex sensitivity, resulted in a partial but significant recovery of baroreflex gain, as demonstrated by improvements in AP50, the lower plateau, and HR range. Conclusion: In summary, our results indicate that long-term administration of the non-bacterial fraction of kefir promotes a significant decrease in both MAP and HR, by improving baroreflex, and reduces cardiac hypertrophy in SHRs, likely via ACE inhibition, and reduction of the TNF-α-to-IL10 ratio.

Original languageEnglish (US)
Pages (from-to)66-72
Number of pages7
JournalNutrition
Volume51-52
DOIs
StatePublished - Jul 1 2018

Fingerprint

Baroreflex
Cardiomegaly
Peptidyl-Dipeptidase A
Inbred SHR Rats
Blood Pressure
Arterial Pressure
Interleukin-10
Kefir
Milk
Cytokines
Nitroprusside
Phenylephrine
Anti-Inflammatory Agents
Heart Rate

Keywords

  • Baroreflex gain
  • Bioactive peptides
  • Cardiac hypertrophy
  • Fermented milk
  • Hypertension

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity. / Brasil, Girlandia Alexandre; Silva-Cutini, Mirian de Almeida; Moraes, Flávia de Souza Andrade; Pereira, Thiago de Melo Costa; Vasquez, Elisardo Corral; Lenz, Dominik; Bissoli, Nazaré Souza; Endringer, Denise Coutinho; de Lima, Ewelyne Miranda; Biancardi, Vinicia Campana; Maia, June Ferreira; de Andrade, Tadeu Uggere.

In: Nutrition, Vol. 51-52, 01.07.2018, p. 66-72.

Research output: Contribution to journalArticle

Brasil, GA, Silva-Cutini, MDA, Moraes, FDSA, Pereira, TDMC, Vasquez, EC, Lenz, D, Bissoli, NS, Endringer, DC, de Lima, EM, Biancardi, VC, Maia, JF & de Andrade, TU 2018, 'The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity', Nutrition, vol. 51-52, pp. 66-72. https://doi.org/10.1016/j.nut.2017.12.007
Brasil, Girlandia Alexandre ; Silva-Cutini, Mirian de Almeida ; Moraes, Flávia de Souza Andrade ; Pereira, Thiago de Melo Costa ; Vasquez, Elisardo Corral ; Lenz, Dominik ; Bissoli, Nazaré Souza ; Endringer, Denise Coutinho ; de Lima, Ewelyne Miranda ; Biancardi, Vinicia Campana ; Maia, June Ferreira ; de Andrade, Tadeu Uggere. / The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity. In: Nutrition. 2018 ; Vol. 51-52. pp. 66-72.
@article{6cf79e62604e46b1af112a632c609fa8,
title = "The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity",
abstract = "Objectives: We aimed to evaluate whether long-term treatment with the soluble non-bacterial fraction of kefir affects mean arterial pressure (MAP) and cardiac hypertrophy through the modulation of baroreflex sensitivity, ACE activity, and the inflammatory-to-anti-inflammatory cytokine ratio in spontaneously hypertensive rats (SHRs). Methods: SHRs were treated with the soluble non-bacterial kefir fraction (SHR-kefir) or with kefir vehicle (SHR-soluble fraction of milk). Normotensive control Wistar Kyoto animals received the soluble fraction of milk. All treatments were administered by gavage (0.3 mL/100g/body weight), once daily for eight weeks. At the end, after basal MAP and Heart Rate (HT) measurement, barorreflex sensitivity was evaluated through in bolus administrations of sodium nitroprusside and phenylephrine (AP50 [arterial pressure 50{\%}], the lower plateau, and HR range were measured). ACE activity and cytokines (TNF-α and IL-10) were evaluated by ELISA. Cardiac hypertrophy was analysed morphometrically. Results: Compared to SHR control, SHR-kefir exhibited a significant decrease in both MAP (SHR: 184 ± 5; SHR-Kefir: 142 ± 8 mmHg), and HR (SHR: 360 ± 10; SHR-kefir: 310 ± 14 bpm). The non-bacterial fraction of kefir also reduced cardiac hypertrophy, TNF-α-to-IL10 ratio, and ACE activity in SHRs. SHR-kefir baroreflex sensitivity, resulted in a partial but significant recovery of baroreflex gain, as demonstrated by improvements in AP50, the lower plateau, and HR range. Conclusion: In summary, our results indicate that long-term administration of the non-bacterial fraction of kefir promotes a significant decrease in both MAP and HR, by improving baroreflex, and reduces cardiac hypertrophy in SHRs, likely via ACE inhibition, and reduction of the TNF-α-to-IL10 ratio.",
keywords = "Baroreflex gain, Bioactive peptides, Cardiac hypertrophy, Fermented milk, Hypertension",
author = "Brasil, {Girlandia Alexandre} and Silva-Cutini, {Mirian de Almeida} and Moraes, {Fl{\'a}via de Souza Andrade} and Pereira, {Thiago de Melo Costa} and Vasquez, {Elisardo Corral} and Dominik Lenz and Bissoli, {Nazar{\'e} Souza} and Endringer, {Denise Coutinho} and {de Lima}, {Ewelyne Miranda} and Biancardi, {Vinicia Campana} and Maia, {June Ferreira} and {de Andrade}, {Tadeu Uggere}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.nut.2017.12.007",
language = "English (US)",
volume = "51-52",
pages = "66--72",
journal = "Nutrition",
issn = "0899-9007",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - The benefits of soluble non-bacterial fraction of kefir on blood pressure and cardiac hypertrophy in hypertensive rats are mediated by an increase in baroreflex sensitivity and decrease in angiotensin-converting enzyme activity

AU - Brasil, Girlandia Alexandre

AU - Silva-Cutini, Mirian de Almeida

AU - Moraes, Flávia de Souza Andrade

AU - Pereira, Thiago de Melo Costa

AU - Vasquez, Elisardo Corral

AU - Lenz, Dominik

AU - Bissoli, Nazaré Souza

AU - Endringer, Denise Coutinho

AU - de Lima, Ewelyne Miranda

AU - Biancardi, Vinicia Campana

AU - Maia, June Ferreira

AU - de Andrade, Tadeu Uggere

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objectives: We aimed to evaluate whether long-term treatment with the soluble non-bacterial fraction of kefir affects mean arterial pressure (MAP) and cardiac hypertrophy through the modulation of baroreflex sensitivity, ACE activity, and the inflammatory-to-anti-inflammatory cytokine ratio in spontaneously hypertensive rats (SHRs). Methods: SHRs were treated with the soluble non-bacterial kefir fraction (SHR-kefir) or with kefir vehicle (SHR-soluble fraction of milk). Normotensive control Wistar Kyoto animals received the soluble fraction of milk. All treatments were administered by gavage (0.3 mL/100g/body weight), once daily for eight weeks. At the end, after basal MAP and Heart Rate (HT) measurement, barorreflex sensitivity was evaluated through in bolus administrations of sodium nitroprusside and phenylephrine (AP50 [arterial pressure 50%], the lower plateau, and HR range were measured). ACE activity and cytokines (TNF-α and IL-10) were evaluated by ELISA. Cardiac hypertrophy was analysed morphometrically. Results: Compared to SHR control, SHR-kefir exhibited a significant decrease in both MAP (SHR: 184 ± 5; SHR-Kefir: 142 ± 8 mmHg), and HR (SHR: 360 ± 10; SHR-kefir: 310 ± 14 bpm). The non-bacterial fraction of kefir also reduced cardiac hypertrophy, TNF-α-to-IL10 ratio, and ACE activity in SHRs. SHR-kefir baroreflex sensitivity, resulted in a partial but significant recovery of baroreflex gain, as demonstrated by improvements in AP50, the lower plateau, and HR range. Conclusion: In summary, our results indicate that long-term administration of the non-bacterial fraction of kefir promotes a significant decrease in both MAP and HR, by improving baroreflex, and reduces cardiac hypertrophy in SHRs, likely via ACE inhibition, and reduction of the TNF-α-to-IL10 ratio.

AB - Objectives: We aimed to evaluate whether long-term treatment with the soluble non-bacterial fraction of kefir affects mean arterial pressure (MAP) and cardiac hypertrophy through the modulation of baroreflex sensitivity, ACE activity, and the inflammatory-to-anti-inflammatory cytokine ratio in spontaneously hypertensive rats (SHRs). Methods: SHRs were treated with the soluble non-bacterial kefir fraction (SHR-kefir) or with kefir vehicle (SHR-soluble fraction of milk). Normotensive control Wistar Kyoto animals received the soluble fraction of milk. All treatments were administered by gavage (0.3 mL/100g/body weight), once daily for eight weeks. At the end, after basal MAP and Heart Rate (HT) measurement, barorreflex sensitivity was evaluated through in bolus administrations of sodium nitroprusside and phenylephrine (AP50 [arterial pressure 50%], the lower plateau, and HR range were measured). ACE activity and cytokines (TNF-α and IL-10) were evaluated by ELISA. Cardiac hypertrophy was analysed morphometrically. Results: Compared to SHR control, SHR-kefir exhibited a significant decrease in both MAP (SHR: 184 ± 5; SHR-Kefir: 142 ± 8 mmHg), and HR (SHR: 360 ± 10; SHR-kefir: 310 ± 14 bpm). The non-bacterial fraction of kefir also reduced cardiac hypertrophy, TNF-α-to-IL10 ratio, and ACE activity in SHRs. SHR-kefir baroreflex sensitivity, resulted in a partial but significant recovery of baroreflex gain, as demonstrated by improvements in AP50, the lower plateau, and HR range. Conclusion: In summary, our results indicate that long-term administration of the non-bacterial fraction of kefir promotes a significant decrease in both MAP and HR, by improving baroreflex, and reduces cardiac hypertrophy in SHRs, likely via ACE inhibition, and reduction of the TNF-α-to-IL10 ratio.

KW - Baroreflex gain

KW - Bioactive peptides

KW - Cardiac hypertrophy

KW - Fermented milk

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=85044579070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044579070&partnerID=8YFLogxK

U2 - 10.1016/j.nut.2017.12.007

DO - 10.1016/j.nut.2017.12.007

M3 - Article

VL - 51-52

SP - 66

EP - 72

JO - Nutrition

JF - Nutrition

SN - 0899-9007

ER -